Syndax Announces Participation in November Investor Conferences

Syndax Pharmaceuticals (Nasdaq: SNDX) announced that CEO Michael A. Metzger and management team members will participate in four November investor conferences.

Rhea-AI Summary

Syndax Pharmaceuticals (Nasdaq: SNDX) announced that CEO Michael A. Metzger and management team members will participate in four November investor conferences.

Fireside chats are scheduled for November 10, 2026 at Guggenheim in Boston, November 12 at Stifel in New York, November 17 at UBS in London and November 19 at Jefferies in London. Live webcasts and limited-time replays will be available on the company’s investor website.

Key Terms

menin inhibitor, monoclonal antibody, csf-1 receptor

3 terms

menin inhibitor medical

"an FDA-approved menin inhibitor"

A menin inhibitor is a type of experimental drug that blocks the action of a protein called menin, which some cancers use to keep growing. Think of it as flipping off a switch that cancer cells rely on to survive; by doing so, these drugs can slow or stop tumor growth. Investors watch menin inhibitors because clinical trial results, regulatory approvals, and market demand determine whether they become valuable cancer treatments and potential revenue drivers.

monoclonal antibody medical

"an FDA-approved monoclonal antibody"

A monoclonal antibody is a laboratory-made protein designed to recognize and attach to a specific target in the body, such as a disease-causing substance or cell. It functions like a highly precise lock-and-key tool, helping to treat or detect illnesses. For investors, companies developing monoclonal antibodies can represent promising opportunities in the healthcare sector, especially as these treatments often address unmet medical needs.

csf-1 receptor medical

"blocks the colony stimulating factor 1 (CSF-1) receptor"

A cell-surface protein found mainly on certain immune cells that acts like a lock for signaling molecules such as colony-stimulating factor 1; when those molecules bind, the receptor tells the cell to grow, move or change behavior. As a biological control point in inflammation, tissue repair and some cancers, it is a common drug target; investors watch drug candidates and clinical results involving the receptor because they can affect the commercial and regulatory prospects of biotech companies.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

NEW YORK, Oct. 30, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer, as well as members of the Syndax management team, will participate in the following upcoming investor conferences:

• Guggenheim 3rd Annual Healthcare Innovation Conference in Boston, MA with a fireside chat on Tuesday, November 10, 2026, at 11:00 a.m. ET.
• Stifel 2026 Healthcare Conference in New York, NY with a fireside chat on Thursday, November 12, 2026, at 9:20 a.m. ET.
• UBS Global Biopharma Conference 2026 in London, UK with a fireside chat on Tuesday, November 17, 2026, at 12:00 p.m. GMT / 7:00 a.m. ET.
• Jefferies London Healthcare Conference in London, UK with a fireside chat on Thursday, November 19, 2026, at 12:30 p.m. GMT / 7:30 a.m. ET.
  
  

A live webcast of the fireside chats will be available in the Investor section of the Company's website at www.syndax.com, where a replay will also be available for a limited time.

About Syndax

Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company advancing innovative cancer therapies. Highlights of the Company's pipeline include Revuforj^® (revumenib), an FDA-approved menin inhibitor, and Niktimvo™ (axatilimab-csfr), an FDA-approved monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. Fueled by our commitment to reimagining cancer care, Syndax is working to unlock the full potential of its pipeline and is conducting several clinical trials across the continuum of treatment. For more information, please visit www.syndax.com or follow the Company on X and LinkedIn.

Syndax Contacts

Sharon Klahre
Syndax Pharmaceuticals, Inc.
sklahre@syndax.com
Tel 781.684.9827

SNDX-G